Skip to main content

Risankizumab Side Effects

Medically reviewed by Philip Thornton, DipPharm. Last updated on Mar 10, 2024.

Applies to risankizumab: parenteral injection for iv infusion, parenteral injection for sub-q use.

Side effects include:

Adverse reactions (≥1%) in patients with plaque psoriasis and psoriatic arthritis: upper respiratory infection, headache, fatigue, injection site reaction, tinea infection.  

Adverse reactions (>3%) in patients receiving induction treatment for Crohn disease: upper respiratory infection, headache, arthralgia.  

Adverse reactions (>3%) in patients receiving maintenance treatment for Crohn disease: arthralgia, injection site reaction, abdominal pain, anemia, pyrexia, back pain, arthropathy, urinary tract infection.

For Healthcare Professionals

Applies to risankizumab: intravenous solution, subcutaneous kit, subcutaneous solution.


Common (1% to 10%): Abdominal pain[Ref]


Common (1% to 10%): Tinea infections (e.g., tinea pedis, tinea cruris, body tinea, tinea versicolor, tinea manuum, tinea infection)

Uncommon (0.1% to 1%): Folliculitis, urticaria

Postmarketing: Eczema, rash[Ref]


Common (1% to 10%): Anemia[Ref]



Common (1% to 10%): Hypersensitivity reactions[Ref]


Very common (10% or more): Immunogenicity (24%), infections (e.g., cellulitis, osteomyelitis, sepsis, herpes zoster) (22%)[Ref]


Common (1% to 10%): Injection site reactions (e.g., bruising, erythema, extravasation, hematoma, hemorrhage, infection, inflammation, irritation, pain, pruritus, reaction, swelling, warmth)[Ref]


Common (1% to 10%): Arthralgia, arthropathy, back pain[Ref]

Nervous system

Common (1% to 10%): Headache (e.g., tension headache, sinus headache, cervicogenic headache)[Ref]


Common (1% to 10%): Fatigue, asthenia, pyrexia[Ref]


Very common (10% or more): Upper respiratory infections (e.g., respiratory tract infection [viral, bacterial, unspecified], sinusitis [including acute], rhinitis, nasopharyngitis, pharyngitis [including viral], tonsillitis) (up to 13%)[Ref]

Frequently asked questions


1. Product Information. Skyrizi (risankizumab). AbbVie US LLC. 2024;SUPPL-32.

2. Product Information. Skyrizi (risankizumab). AbbVie US LLC. 2019.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.